Browsing Tag
Vepdegestrant
3 posts
Can vepdegestrant outperform elacestrant in the race for ESR1-mutant breast cancer dominance?
Vepdegestrant shows stronger PFS benefit than elacestrant in ESR1-mutant breast cancer. Can it become the new standard? Explore data, safety, and market outlook.
PROTAC vs SERD: Is protein degradation the future of endocrine resistance treatment?
Vepdegestrant challenges oral SERDs with PROTAC innovation. Explore trial results, safety, and the future of protein degradation in breast cancer care.
Vepdegestrant delivers Phase 3 success for Arvinas and Pfizer in ESR1-mutant breast cancer
Vepdegestrant shows 43% risk reduction in ESR1-mutant breast cancer vs fulvestrant. Learn how Arvinas and Pfizer aim for FDA filing in H2 2025.